Buflomedil

Buflomedil, a vasodilator agent, is an orally active α1A-adrenoceptor antagonist with Kis of 4.06 µM and 6.84 µM for α1A-AR and α1B-AR, respectively. Buflomedil can be used for the study of peripheral circulatory disorders[1][2].

Product Specifications

CAS Number

[55837-25-7]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/buflomedil.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=C(OC)C=C(OC)C=C1OC)CCCN2CCCC2

Molecular Formula

C17H25NO4

Molecular Weight

307.38

Precautions

P261-P280-P302+P352

References & Citations

[1]de Backer TL, et al. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2013 Mar 28;2013 (3) :CD000988.|[2]Limbs International Medicinal Buflomedil (LIMB) Study Group; Leizorovicz A, Becker F. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. Circulation. 2008 Feb 12;117 (6) :816-22.|[3]Tang LM, et al. Inhibitory effect of buflomedil on prostate alpha1A adrenoceptor in the Wistar rat. Neurosci Lett. 2004 Sep 2;367 (2) :224-7.